merkel cell carcinoma

Morphogenesis, Inc., a biotechnology company focused on developing cancer vaccines, in partnership with CohBar, believes they have met their milestone with IFx-HU2.0, a cancer vaccine studied in advanced Merkel cell carcinoma and squamous cell carcinoma.